Enlivex Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.2156
-0.0068 (-3.06%)
At close: Oct 14, 2026, 4:00 PM EDT
0.2210
+0.0054 (2.50%)
After-hours: Oct 14, 2026, 7:33 PM EDT
Company Description
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026.
The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Enlivex Ltd.
| Country | Israel |
| Founded | 2005 |
| IPO Date | Dec 12, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Oren Hershkovitz |
Contact Details
Address: 14 Einstein Street Ness Ziona, 7403618 Israel | |
| Phone | 972 2 620 8072 |
| Website | enlivex.com |
Stock Details
| Ticker Symbol | ENLV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001596812 |
| CUSIP Number | M20156127 |
| ISIN Number | IL0011319527 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
| Shai Novik M.B.A. | Executive Chairman |
| Prof. Dror Mevorach M.D. | Founder and Scientific Advisor |
| Shachar Shlosberger CPA | Chief Financial Officer |
| Dr. Veronique Amor-Baroukh | Chief Operating Officer |
| Sigal Arad | Director of Human Resources |
| Dr. Einat Galamidi M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 2, 2026 | 6-K/A | Filing |
| Oct 1, 2026 | 6-K/A | Filing |
| Sep 29, 2026 | 6-K | Report of foreign issuer |
| Sep 25, 2026 | 6-K | Report of foreign issuer |
| Sep 22, 2026 | 6-K | Report of foreign issuer |
| Aug 17, 2026 | 424B3 | Prospectus |
| Aug 13, 2026 | EFFECT | Notice of Effectiveness |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | 6-K | Report of foreign issuer |
| Aug 6, 2026 | F-3 | Filing |